P.O. Box 12878
Research Triangle Park
127 articles with SCYNEXIS, Inc.
SCYNEXIS Reports Positive Results from Phase 2b Dose-Finding Study of Oral SCY-078 in Vulvovaginal Candidiasis
Clinically and mycologically effective and well-tolerated oral dose of SCY-078 identified for use in Phase 3 registration program.
FDA’s Approval of T2 Biosystems T2Bacteria Panel Underlines Importance of Sepsis Diagnosis and Tr...
7/10/2018On May 29, the FDA cleared T2 Biosystems’ T2Bacteria Panel for diagnosis of sepsis. In that sepsis is the third-leading cause of death in the U.S., this emphasizes the importance of work in this area.
20th International Symposium on Infections in the Immunocompromised Host (ICHS)
SCYNEXIS, Inc. announced the presentation of data at American Society for Microbiology (ASM) Microbe 2018
SCYNEXIS Announces the Publication of Phase 1 Study Results for SCY-078 in The Journal of Clinical Pharmacology
New study results demonstrate low risk of interactions between SCY-078 and drugs metabolized by CYP enzymes
SCYNEXIS, Inc. today announced that Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will participate in a panel at the 2018 BIO International Conference at the Boston Convention and Exhibition Center on Wednesday, June 6, 2018 from 4:15 - 5:15 p.m. ET.
Enrollment complete in Phase 2b DOVE study in VVC; on-track for top-line data by July 2018
On May 1, the U.S. Food and Drug Administration (FDA) granted Scynexi’s oral formulation of SCY-078 to treat vulvovaginal candidiasis (VVC) and recurrent VVC both Qualified Infectious Diseases Product (QIDP) and Fast Track Designation.
SCYNEXIS's Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention of Recurrent VVC
QIDP provides five additional years of market exclusivity, and Fast Track expedites the regulatory path Enrollment completed in Phase 2b DOVE study in VVC; on-track for top-line data by July 2018 Initiation of Phase 3 registration program in VVC planned for the fourth quarter of 2018, with potential NDA filing in 2020
SCYNEXIS Data Presentations at ECCMID 2018 Show SCY-078 Potent and Synergistic Antifungal Activity Against Aspergillus and Pneumocystis
SCYNEXIS, Inc. announced data presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 21-24, 2018, in Madrid, Spain.
SCYNEXIS, Inc. reported financial results for the year ended December 31, 2017, and provided an update on recent operational and clinical developments.
SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the pricing of its underwritten public offering of common stock and warrants.
SCYNEXIS Presents New In Vivo Data Highlighting the Potential of SCY-078 Used in Combination for the Treatment of Aspergillus Infections at AAA 2018
These results further confirm in vitro data that demonstrated the synergistic and additive activity of SCY-078 in combination with ISA against Aspergillus spp.
SCYNEXIS today provided a corporate update, including recent pipeline developments and anticipated milestones in 2018, for its lead antifungal candidate, SCT-078.
SCYNEXIS today announced that the Company will participate in two upcoming investor conferences.
Mr. Sukenick will be responsible for leading the Company's corporate strategic and tactical legal initiatives, including intellectual property and compliance.
SCYNEXIS today reported financial results for the quarter ended September 30, 2017, and provided an update on recent operational and clinical developments.
SCYNEXIS, Inc. Presents New Data Further Supporting SCY-078 As A Potential Treatment For Aspergillus And Candida Infections At IDWeek 2017
SCYNEXIS, Inc. Presents New Data Supporting Oral SCY-078 For The Clinical Treatment Of Vulvovaginal Candidiasis Infections At The 2017 IDSOG Annual Meeting